ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2016 American Transplant Congress

    Denosumab Prevents Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: Results from a Randomized Controlled Trial.

    M. Bonani,1 D. Frey,2 J. Brockmann,3 T. Fehr,1 T. Müller,1 N. Graf,4 R. Wüthrich.1

    1Division of Nephrology, University Hospital Zurich, Zurich, Switzerland; 2Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland; 3Division of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland; 4Graf Biostatistics, Winterthur, Switzerland.

    Background: Kidney transplantation is associated with bone loss and an increased risk of fracture. Since current therapeutic options to prevent bone loss are limited we…
  • 2016 American Transplant Congress

    Associations of Risk Factors and Kidney Retransplant Outcomes Vary Between Three Common Induction Agents: Results from the Analysis of Over Ten-Thousand Cases in Ten Years.

    A. Santos, X. Wen, M. Casey, S. Rehman, K. Womer.

    Medicine, University of Florida, Gainesville, FL.

    BACKGROUND: There is no published study comparing the significance of risk factors for graft outcomes associated with common induction regimens combined with tacrolimus and mycophenolate…
  • 2016 American Transplant Congress

    Increasing Tacrolimus Time-in-Therapeutic Range Is Associated with Less Cellular Rejection in Lung Transplant Recipients.

    C. Ensor, K. Harrigan, R. Venkataramanan, M. Morrell, C. Moore, J. Hayanga, M. Crespo, J. DCunha, A. Zeevi, J. McDyer.

    University of Pittsburgh, Pittsburgh, PA.

    Purpose: To describe the effect of tacrolimus (FK) time-in-therapeutic range (TTR) on incidence of cellular rejection (ACR) within the first year after lung transplantation (LT).Methods:…
  • 2016 American Transplant Congress

    Serelaxin Decreases the Severity of Cold Ischemia-Reperfusion Injury After Liver Transplantation in Mice.

    S. Kageyama, K. Nakamura, R. Busuttil, J. Kupiec-Weglinski.

    The Dumont-UCLA Transplantation Center, UCLA, Los Angeles, CA.

    Background. Extended cold preservation contributes to ischemia-reperfusion injury (IRI), which impairs graft function and leads to poor clinical outcomes. Serelaxin (SER), a recombinant form of…
  • 2016 American Transplant Congress

    Prevalence of Polyreactive Innate-Like B Cells Among Graft-Infiltrating B Cells in Human Cardiac Allograft Vasculopathy.

    D. Chatterjee,1 C. Moore,2 B. Gao,3 K. Clerkin,1 S. See,1 D. Shaked,1 K. Rogers,1 S. Nunez,1 Y. Veras,1 L. Addonizio,1 M. Givertz,4 Y. Naka,1 D. Mancini,1 R. Vasilescu,5 C. Marboe,5 S. Restaino,1 J. Madsen,2 E. Zorn.1

    1Medicine, Columbia University Medical Center, NY, NY; 2Massachusetts General Hospital Transplant Center, Boston; 3First Hospital of Jilin University, Changchun, China; 4Brigham and Women's Hospital, Boston; 5Pathology & Cell Biology, Columbia University Medical Center, NY.

    Cardiac allograft vasculopathy (CAV) is a leading cause of death in long-term heart transplant survivors. Dense B cell infiltrates are common in heart transplants with…
  • 2016 American Transplant Congress

    Criteria for the Diagnosis of Microvascular Inflammation (MVI) in Kidney Transplant Biopsies (KTxBx).

    J. Grande,1 R. Leduc,2 The DeKAF Study Group.

    1Dept. of Lab Medicine & Pathology, Mayo Clinic College of Medicine, Rochester, MN; 2Division of Biostatistics, U. Minnesota School of Public Health, Minneapolis, MN.

    The presence of MVI (Banff glomerulitis "g" score and Banff peritubular capillary "ptc" score) in KTxBx, often related to antibody mediated rejection (AMR), is associated…
  • 2016 American Transplant Congress

    Impact of Machine Perfusion on Long-Term Kidney Transplant Outcomes.

    S. Sandal,1,2 X. Luo,2 A. Massie,2 M. Cantarovich,1 D. Segev.2

    1MUHC, Montreal, Canada; 2JHU, Baltimore.

    Machine perfusion (MP) has been shown to decrease DGF rates in kidney transplant (KT) recipients when compared with static cold storage (CS). However, there is…
  • 2016 American Transplant Congress

    Complement-Binding Donor-Specific Anti-HLA Antibodies Are Associated with Severe Kidney Allograft Arteriosclerosis.

    A. Loupy,1 D. Viglietti,2 J. Duong Van Huyen,1 D. Glotz,2 C. Legendre,1 A. Zeevi,3 C. Lefaucheur.2

    1Necker Hospital, Paris, France; 2Saint-Louis Hospital, Paris, France; 3University of Pittsburgh Medical Center, Pittsburgh.

    The role of circulating donor-specific anti-HLA antibodies (DSA) in the development of accelerated arteriosclerosis have been recently reported in kidney transplant recipients. This study investigated…
  • 2016 American Transplant Congress

    An Economical and Effective Vaccination Program in Patients Transplanted for Hepatitis B Virus Related Liver Diseases: A Prospective Study.

    W. Ju, A. Yang, Q. Ren, D. Wang, Z. Guo, Y. Ma, A. Hu, Q. Tai, X. Zhu, X. He.

    Organ Transplantation Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

    Aims: To prospectively investigate the efficacy and safety of procedural HBV vaccination in patients transplanted for HBV related liver diseases for prevention of hepatitis B…
  • 2016 American Transplant Congress

    Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients.

    C. Legendre,1 J. Campistol,2 T. Feldkamp,3 J. Wang,4 G. Remuzzi,5 L. Weekers,6 N. Sheerin.7

    1Université Paris Descartes & Hôpital Necker, Paris, France; 2Hospital Clinic, University of Barcelona, Barcelona, Spain; 3University Hospital Schleswig-Holstein, Kiel, Germany; 4Alexion Pharmaceuticals, Inc., Cheshire, CT; 5IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy; 6CHU de Liège, Liège, Belgium; 7Newcastle University, Newcastle upon Tyne, United Kingdom.

    Purpose: aHUS often progresses to ESRD and requires transplant (tx). Eculiumab (ECU), a terminal complement inhibitor, inhibits TMA irrespective of tx status. We evaluated outcomes…
  • « Previous Page
  • 1
  • …
  • 76
  • 77
  • 78
  • 79
  • 80
  • …
  • 180
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences